An observational study in Muscular Atrophy, Spinal, sponsored by Biogen. Recruiting at 14 sites in 2 countries. Open to female participants aged 18 Years to 54 Years. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Biogen · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Muscular Atrophy, Spinal by Biogen — 5 open to participants now, 10 under way, 4 of them phase 3. Muscular Atrophy, Spinal · Biogen.
Among the 27 studies in Muscular Atrophy, Spinal by Biogen, this one is one of 2 that started in 2023, is one of 5 observational ones, and was the 23rd registered.
282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.
Browse Muscular Atrophy, Spinal studies →5 of the 27 studies in Muscular Atrophy, Spinal by Biogen are open now, in 12 countries. Recruiting first, the newest first:
Biogen · Sites in United States
Ages 0 days–7 mo
Biogen · Sites in United States, Brazil, China and 2 more countries
Ages 15–60
Biogen · Sites in United States, Australia, Brazil and 4 more countries
Ages 0 days–42 days
Biogen · Sites in United States, France, Germany and 4 more countries
Ages 3+
By country, each count listing its studies:
Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 54 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 4 · Phase 3 9 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 20 is below the median of 139 across 114 observational studies indexed under Muscular Atrophy, Spinal.
Median enrollment 47 across the 21 interventional studies, 74 across the 5 observational. Of the 16 that completed or were terminated, 9 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
4 of the studies in Muscular Atrophy, Spinal by Biogen that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05067790Phase 3BiogenA Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) | 2027-09-24 |
| NCT04317794BiogenA Study of the Safety of Nusinersen (Spinraza®) and Its Effects on Motor Function in Koreans Living With SMA Treated During Their Usual Medical Care | 2027-02-05 |
| NCT05042921BiogenPediatric Spinal Muscular Atrophy (SMA) China Registry | 2027-09-02 |
| NCT06555419BiogenA Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK) | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies in Muscular Atrophy, Spinal by Biogen, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, researchers will know more about the effects of nusinersen, also known as Spinraza®, in pregnant participants with spinal muscular atrophy, also known as SMA. This is a drug available for doctors to prescribe for people with SMA. Due to the current treatment options that exist, people with SMA may now reach the age where they can become pregnant. But, there is not enough information known yet about what the effects of nusinersen may be on pregnant people with SMA or on their babies.
This is known as an "observational" study, which collects health information about study participants without changing their medical care. The pregnant participants for this study will be found using 3 different groups of SMA study research centers:
The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are:
The main questions researchers want to learn about in this study are:
Researchers will also compare this information to people without SMA who have not received nusinersen.
This study will be done as follows:
The primary objectives of the study are to prospectively evaluate pregnancy complications and outcomes in participants with SMA, birth outcomes and adverse effects in infants born to participants with SMA, who were exposed to nusinersen 12 or 50/28 milligrams (mg) up to 14 months prior to the first day of their last menstrual period (LMP) before conception, 14.5 months before the date of conception, and/or at any time during their pregnancy. The secondary objective of the study is to evaluate pregnancy outcomes in participants with SMA exposed to nusinersen 12 or 50/28 mg as compared with participants without SMA who were not exposed to nusinersen (e.g., participants from external, general population comparators).
The criteria were revised on the registry on Nov 12, 2026. See what changed
Pregnant participants with SMA who are exposed to nusinersen from the UK Adult SMA REACH, ISMAR - US, SMArtCARE, and Polish SMA Patient registries will be enrolled to obtain information on effects of nusinersen on pregnancy complications and outcomes.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Pregnant participants with SMA who are exposed to 12 or 50/28 mg nusinersen during the relevant window defined as 14 months prior to the first day of the participant's last menstrual period before conception, 14.5 months before conception and anytime during pregnancy and are enrolled in the registries, International Spinal Muscular Atrophy Registry (ISMAR), Adult SMA REACH, SMArtCARE and Polish SMA Patient registry will be followed prospectively up to 3 months post-delivery, the infants will be followed up to 2 years post-delivery and the available data is collected retrospectively.
Other: No Intervention
Administered as specified in the treatment arm.
Number of Pregnancy Terminations
Pregnancy termination is defined as any induced or voluntary fetal loss during pregnancy.
Time frame: Up to 10 years
Number of Spontaneous Abortions
Spontaneous abortion is defined as any loss of a fetus due to natural causes at \<20 weeks of gestation.
Time frame: Up to 10 years
Number of Fetal Deaths
Fetal deaths include early fetal loss which is fetal death occurring at ≥20 weeks but \<28 weeks of gestation and late fetal loss which is fetal death occurring at ≥28 weeks of gestation.
Time frame: Up to 10 years
Number of Live Births
Live births include premature births which is defined as delivery at \<37 weeks of gestation, full term birth which is defined as delivery at ≥37 weeks of gestation.
Time frame: Up to 10 years
Number of Neonatal, Perinatal, and Infant Deaths
Neonatal death is defined as death occurring in a newborn prior to 28 days after birth. Perinatal death is defined as death occurring at or after 28 days and prior to 12 weeks after birth. Infant death is defined as death occurring between 12 and 52 weeks after birth, inclusive.
Time frame: Up to 10 years
Number of Major Congenital Malformations (MCMs)
MCMs (interchangeably referred to as congenital malformations, congenital anomalies, and birth defects) are abnormalities in structural development that are medically or cosmetically significant, are present at birth, and persist in postnatal life unless or until repaired.
Time frame: Up to 10 years
Number of Infants Small for Gestational Age Birth
Birth weight will be classified as small for gestational age (\<10th percentile), appropriate (10th-90th percentile), or large (\>90th percentile).
Time frame: Up to 10 years
Number of Ectopic and Molar Pregnancies
Ectopic pregnancy is defined as a pregnancy that occurs outside of the uterine cavity. Molar pregnancy is defined as genetically abnormal conceptions characterized by abnormal chorionic villi, trophoblastic hyperplasia, poor fetal development, and an increased risk of malignant disease development.
Time frame: Up to 10 years
Number of Maternal Deaths
Maternal deaths during pregnancy, labor, delivery, or up to 12 weeks after delivery will be reported.
Time frame: Up to 10 years
Number of Infants With Abnormal Postnatal Growth and Development and Neurobehavioral Impairment
Abnormal postnatal growth and development and neurobehavioral impairment in infants up to 24 months of age will be reported.
Time frame: Up to 10 years
Not enrolling at this site.
Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Oct 2032, 106 months after the start.
Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 106 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.